Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Going to the places you describe is standard fare...those are “essential” businesses. Every time I go, all are packed with people. Not sure that is doing something about it. Sounds like you are following the rules!
Perhaps you could volunteer to help those that have it, no need for mask or anything. It would be a noble effort and show people that you are unafraid...kinda like a mother Teresa role model?
Im not a flu vaccine guy either, but based on your age, bet you had a polio vaccine and possibly small pox vac.
Why are you only mentioning all of this now...why not a few weeks ago? Is it because of the latest conspiracy theory?
Leftist piece of garbage...yet the government is encouraging bp to develop a covid19 vaccine...why is that, after all it’s a right wing admin.
According to TipRanks.com, Byrnes ‘ ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -19.7% and a 24.3% success rate. Byrnes covers the Healthcare sector,
Larrybird...you might want to talk to markman about your settlement ideas...
Invest....you should consider trading the stock.. after holding for 7 years I decided to quit swimming upstream and go with the flow a few months ago.
Ilove...in the bag. Same thought process prior to patent ruling. I will keep my powder dry and my finger loose...
Dude you definitely have your share...it’s amazing this guy says the sky is blue and many look up and say..your right, it is blue what a great call? He’s wrong half the time, just like kiwi pointed out that on 4/9 this dude called for the markets going much lower...yet here we are. Doesn’t take a rocket scientist to figure most likely the pps will drop after the earnings call. Although, I do admit He is very good at making claims after the fact
So tasty...are you saying docs and pharmacists and insurers can’t prescribe/substitute off label?
Larry...what does it cost to develop V’s market? Who has deeper pockets...generics or Amarin? When generics filed andas...how long do you think they thought approval and entering V’s market would take?
I just don’t see how a settlement benefits generics unless it’s too costly for Amarin. The marine and anchor markets seemed like a roll of the dice being that they are the same drug, and questionable patents.., mgmt fcked up Biggs did I for believing the supposedly high probability of a win
Postes....what are they going to do? Unless I’m missing something, with FDA anda approved...start manufacturing and selling. If not, why did they submit anda’s?
Settlement....if I’m H and R, what’s my incentive for settling? To gain a year or two? 50/50 chance on reversal, more cash on hand than Amarin....I don’t see it. Mgmt missed their chance for settlement.
Appellant entries....where the heck is Saul...or his brother Chuck...we need Chuck!
Maybe JL can get some old white judges with Vietnam experience on the appeal...only to see them remand back to district court ??.
BB...this msg board is not the market...you are preaching to the wrong audience. This board only serves to exchange ideas and complain. Neither of which moves the market.
I have never bought calls for AMRN....I have bought calls and did well. However, they were long term (10-14 months out and the premiums were quite low at the time. Looking to be a writer now.
Roth Capital analyst Yasmeen Rahimi hosted a call with leading patent lawyer Shashank Upadhye to dive into the nuances behind the recent District Court ruling in favor of generics, as well as strategy and prospects surrounding Amarin's intended appeal to the Federal Court. The analyst notes that Upadhye puts high Probability of Success on Amarin's appeal, with "a winning appeal argument" likely focusing on District Court's take on primary versus secondary considerations. Rahimi has a Buy rating and a $31 price target on the shares. From stocktwits
covid19..second wave..and some Asian countries are reporting a rise in new cases after a decline, suggesting that a second wave of infections may be on the way.
Not exactly encouraging for the people or the markets....
Good morning Vietnam...for those that have seen the movie, our esteemed retired plastic surgeon would have personified the character “Dick”, who was robin williams characters NCO. I will leave it that...but just know not all of us who served are bigots.
Hdg...good summation...you did not include shifting of burden of proof, why is that?
So eight...what do you expect Covington’s play to be on appeal?
I just said goodbye to my best friend, Alex the beagle. The more you love, the deeper the pain. Never easy.
Captn ..i had the same thoughts...if you look up reasons for converting, #2 is current ira account is low lol. #3 is no rmd!
Hama, seems like a logical prediction on appeal. Wondering tho if reduceit cv reduction as an unexpected result and unmet need as a secondary consideration be part of the appeal, as some here have determined that Judge Du allowed it as evidence, but did not consider it in her decision.
Amarin appeal...does anyone know what strategy Covington (assuming their services are still being used) will pursue on appeal? Everything being mentioned so far is just industry opinions...
Canes, I agree. I’m seeing the same as you. Some people gotta be drama queens.
Eight...too bad all this law did not surface prior to the decision....could have saved me quite a bit of $
Eight...your quote
“small-NO b/c USPTO uses different method to evaluate patent. USPTO evaluates first primary consideration. Court has more lenient by analyzing primary and secondary considerations TOGETHER. “.
Your comment here said uspto evaluates first primary consideration, but you make it sound only the court can consider both primary and secondary.....well from the way I understand it, that’s not true as evidenced by the fact that the uspto did consider secondary after initial rejection based on obviousness and this granted patent because of unexpected result.
I do realize that judge du did not weigh primary and secondary at the same time as outlined by case law, nor did she shift the burden of proof to the generic regarding the secondary considerations.
Was just trying to establish clarity her.e. :)
Eight...are you sure about that? Amarin successfully got patent from uspto after being rejected on obviousness by the uspto, by helping the patent examiner see “an unexpected result”...that being a reduction of apo-b. Secondary consideration includes “unexpected result”.
Nick...this dilemma regarding backdoor to reduce it patient population by the generics was always a concern to me because vascepa is the same drug for both Indications (marine and reduce it). So it appears the only strategy the company had to fend off competition was thru patents? What if patents failed...as happened regardless of Judge Du’s opinion (which by the way is a bitter pill to swallow that one opinion can do this much damage). Management had no backup plan for the anchor spa in 2013 either which pissed me off. Business 101...always have a backup plan if the answer is NO!
Kiwi....looking forward, isn’t this patent dispute limited to the marine indication..I.e...over 500 tgs? If so the market isn’t that large.. So looking forward, how can amarin keep generics from entering the reduce it indication, i.e., 150-500 Tgs with cv reduction labeling? Isn’t that what we care about the most?
Eight, wrong methodology used...which is the procedural error mentioned by patent attorney and law professor on the Jeffries call, which stands a better chance (50-64%) of winning on appeal. What gets me is that according to the expert, the Supreme Court dictated what methodology to use at the fed district ct for patent litigation, and judge du did not use it, but rather took on the methodology the uspto would have used...a mistake that has taken place many times in the past, therefore the Supreme Court involvement in the past. I am encouraged by this finding, however if the appellate court doesn’t have judges appointed to the case that are sticklers for procedure...then chances of winning drop. Anyways that’s my two cents from the Jeffries call.
Du's rebuttal to Markman....except that strong evidence is debatable here as others have pointed out with the Mori study, an obscure trial at best
I avoided an 800k hit by selling all of my stock....sure you did Wilbur...those purchases at 14.80 and 9-10 were just small nibbles right...lol
Capt, aren’t the insurers already substituting gl for vascepa? As well as pharmacists?
Now is the time for JT to be picking up the phone and calling the fine folks over at AstraZeneca...they really wanted in on this cardio space....deeper pockets to handle the appeal.
My plan is to take the ball from the schoolyard. So we go back to .78 cents, and then all of us who are on V no longer get it?
$8-$12billion. If they’re smart and fast. If BP hadn’t stepped up to make an offer prior to the ruling, as was pointed out so many times before...why would they do that now? Why would they want to take on a company handicapped by an appeals process that could be ongoing for years? Seems an injunction would provide certainty as to keeping generics at bay, but that may only cover a couple years, and the anda filings taking a couple years for approval as well as launch seems like a reach when it comes to convincing BP there’s a great risk reward here.
Just thinking out loud here, as I’m weighing my options like so many here are...
Dmiller let me guess...you sold before the close right? Lol
Quote:
“You have no idea what I bought back in the 9-10 area. You only know what I want you to know. “